We experienced a case of PPFE who developed fatal acute deterioration of the disease. Postmortem histologic exam suggested possible novel pathophysiology in acute exacerbation of the disease. Methods: Retrospective analysis the clinical data of 45 diabetic patients with IPF, to explore the characters of clinical manifestation, pulmonary function, chest radiology, laboratory examination and pathological examination and to summarize the prognosis.
The second hospital of JiLin University, China Background and Aims: To explore the clinical features, treatment and prognosis of diabetic patients with idiopathic pulmonary fibrosis (IPF).
Methods: Retrospective analysis the clinical data of 45 diabetic patients with IPF, to explore the characters of clinical manifestation, pulmonary function, chest radiology, laboratory examination and pathological examination and to summarize the prognosis.
Results: Patients showed progressive dyspnea and cough, and some (75.6%) had hypoxemia. The lung function of the patients present with the restricted ventilation 75.6%( 34 /45), diffuse function 64.4%( 29 /45) and small airway obstruction 60.0% ( 27 /45). The lung CT of these patients showed lung multiple grid and strip shape. 22 routine bronchoscopic lung biopsy showed more neutrophils infiltrating in pathological examination. 40 patients received oral hypoglycaemic drugs or hypodermic injection of insulin to control blood sugar. Glucocorticoids were used in 36 patients. The 40 patients (88.9%) improved, and 5 patients (11.1%) died of respiratory failure.
Conclusion:
For diabetic patients, lung function and chest radiography should be checked regularly to find IPF early. For diabetic patients with IPF, it is recommended that intravenous use or inhalation of small doses of glucocorticoid to improve prognosis on the basis of controlling blood sugar. National Hospital Organization Tokyo National Hospital, Japan Background and Aims: Interstitial pneumonia (IP) is frequently complicated by lung cancer. Despite the regular chest X-ray follow up, lung cancer is often diagnosed at progressive stage in IP patients. We carried out this study to investigate the previous history of chest imaging in advanced lung cancer with IP patients and tried to identify the optimal interval of examination.
AP517

INTERVAL OF PREVIOUS X-RAY EXAMINATION
Methods: Four hundred and twenty-one patients were diagnosed with advanced lung cancer during 2012 to 2014 in Teikyo University Hospital. Among those patients, 22 patients with IP were eligible for current study (lung cancer stage III: n = 7, IV: n = 15) and we retrospectively investigated the previous chest X-ray histories. Patients without previous imaging history were excluded.
Results: Median duration from last chest-X ray examination to diagnosis of lung cancer was 7 months (3 months in stage III (n = 7), 10 m in stage IV). Although the median duration in NSCLC group was 6.8 m, the duration tended to be shorter in SCLC group (4.8 m). The median duration in non-CPFE group was significantly shorter than CPFE group (2.8 vs 7.7 m). In half of cases, tumor shadow could not be identified in last chest X-ray examination.
Conclusion: This study suggests that chest imaging for IP patients should be performed in at least 4 to 6 months interval to detect lung cancer in early stage. Background and Aims: The IPF and NSCLC have an obvious correlation in gene mutation, epigenetics and the of activation specific signalling pathways. The tyrosine kinase pathway which is the important signalling pathway is strongly activated not only in many cancers but also in IPF. The pathway once activated will regulate many important physiological processes, which are associated with the initiation or progression of cancer. In this study, we focused our research on the expression of FGF2/FGFR2, and the downstream ERK1/2/p-ERK1/2 in NSCLC patients, IPF patients and other non-malignant diseases patients to verify the common pathogenesis between the IPF and NSCLC.
Methods: Quantitative reverse transcription-polymerase chain reaction (RT-q PCR) and western blot were used to detect the expression of FGF2, FGFR2, ERK1/2 and p-ERK1/2 in carcinoma tissue and paracarcinoma tissue in NSCLC patients, bronchoalveolar lavage fluid in the IPF patients and the normal control group. The normal control group refers to the patients with the main symptom of cough and confirmed healthy by the bronchoalveolar lavage.
Results: Compared with the para-carcinoma tissue, the ERK1/2 mRNA expression is significantly increased (P < 0.001) in lung carcinoma tissue. Compared with the para-carcinoma tissue, the p-ERK1/2 protein expression in lung carcinoma tissue is significantly increased (P < 0.001).
Compared with the para-carcinoma tissue, the FGF2 mRNA and protein expression in lung carcinoma tissue are significantly increased P < 0.001).Compared with the control group, the FGF2 protein expression in IPF patients'bronchoalveolar lavage fluid is increased (P = 0.010).
Compared with the para-carcinoma tissue, the FGFR2b mRNA is significantly decreased (P < 0.001) and the FGFR2c mRNA and protein Results: A total of 42 patients with HL (10 cases from the chart review and 32 from the published case reports) and 48 patients with other forms of HPs were analyzed. In the HL group, the patients were more likely to have fever compared to other HPs patients (90.4% vs 45.8%, P < 0.001). There was also a significant increase in WBC count (HL vs other HPs; median 13,780/uL vs 8,755/uL, P < 0.001) and C-reactive protein (median 5.30 mg/dl vs 1.51 mg/dL, P < 0.001) in the HL patients. Conversely, the serum KL-6 level was significantly lower in HL patients than in patients with other HPs (median 543 U/mL vs 1,827 U/mL, P < 0.001). The ratio of CD4+ to CD8 cells of bronchoalveolar lavage fluid in HL patients was within the normal range but was higher than that of patients with other HPs (median 1.5 vs 0.3, P < 0.001).
Conclusion: These data indicate that the mechanisms of HL may differ from the other forms of HPs. These findings could help to differentiate HL among HPs cases. Background and Aims: Incidence of tuberculosis is increasing in our region. Sarcoidosis on the other hand is a rare but there is an increase report of cases of sarcoidosis in our region. Both diseases share remarkable similarities in their clinical and radiological presentations but has different treatment strategies. To make matter more complicated, both sarcoidosis and tuberculosis can exist in the same patient and the exact incidence of tuberculosis-sarcoidosis is unknown.
Methods: We present a rare case of a 73-year-old Chinese gentleman who was diagnosis with sarcoidosis and tuberculosis.
Results: This patient is an ex-smoker with underlying chronic kidney disease, type 2 diabetes mellitus, hypertension and dyslipidaemia. He presented with facial numbness and was noted to have hypercalcaemia (corrected Calcium 3.07 mmol/L) with suppressed iPTH. His erythrocyte sedimentation rate was >120 mm/h. There were no respiratory or constitutional symptoms. Chest radiograph showed right upper lobe mass. CT done showed multiple irregular lung nodules of varying sizes, with presence of mediastinal, hilar and abdominal lymph nodes. Endobronchial ultrasound showed a large lymph node at station 4R but did not yield any cytology. Subsequently a CT guided biopsy revealed non-necrotizing granulomatous inflammation. The case was discussed in MDT meeting and the diagnosis of sarcoidosis was made based on hypercalcaemia, histopathology of non-necrotizing granuloma and presence of galaxy sign on CT scan. Patient was started on Prednisolone 20 mg OD. His corrected calcium was 3.45 mmol/L then. However, 2 weeks later, he presented with confusion and recurrent fall with corrected calcium was 3.12 mmol/L. Sputum acid fast bacilli was positive and he was subsequently started on Akurit-4 on top of the prednisolone. 
